Mark Womack, MD
Hematology & Oncology · Chattanooga, TNNPI 1689887788
Payments from drug & device makers
Across 321 payments — averaging $5800.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$754K
- Ipsen Bioscience Inc.$320K
- Eli Lilly$265K
- AbbVie$150K
- Exelixis Inc.$132K
- Mirati Therapeutics, Inc.$80K
- plus $162K from 26 others
Across 3 payments — averaging $1892.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
- Bristol Myers Squibb$616
What the payments were for
- Food & beverage$1,27394%
- Education$846%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $754,338 |
| Ipsen Bioscience Inc. | 65 | $320,261 |
| Eli Lilly | 8 | $264,751 |
| AbbVie | 42 | $149,634 |
| Exelixis Inc. | 38 | $131,600 |
| Mirati Therapeutics, Inc. | 33 | $79,726 |
| Genentech, Inc. | 3 | $69,877 |
| Bristol Myers Squibb | 9 | $41,854 |
| Array Biopharma Inc | 21 | $41,633 |
| Coherus Oncology, Inc. | 4 | $5,815 |
| Merck | 17 | $1,193 |
| Gilead | 3 | $448 |
| Genentech USA, Inc. | 10 | $120 |
| Astellas Pharma US Inc | 3 | $120 |
| Novartis | 5 | $104 |
| Pfizer | 7 | $95 |
| E.r. Squibb & Sons, L.L.C. | 7 | $94 |
| Amgen | 6 | $80 |
| Eisai Inc. | 3 | $65 |
| AVEO Pharmaceuticals, Inc. | 2 | $62 |
| Rigel Pharmaceuticals, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| GSK | 1 | $20 |
| PBG Puerto Rico LLC | 2 | $20 |
| Bayer | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Seagen Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,862,115 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 68 | $907,810 |
| CalquenceAcalabrutinib Maleate | 61 | $818,353 |
| XtandiEnzalutamide | 60 | $765,816 |
| ImbruvicaIbrutinib | 51 | $730,067 |
| PomalystPomalidomide | 28 | $525,028 |
| BrukinsaZanubrutinib | 26 | $386,287 |
| VenclextaVenetoclax | 24 | $270,617 |
| ErleadaApalutamide | 19 | $267,759 |
| JakafiRuxolitinib Phosphate | 19 | $251,401 |
| Abiraterone Acetate | 116 | $239,342 |
| Neulasta OnproPegfilgrastim | 37 | $211,600 |
| TagrissoOsimertinib Mesylate | 11 | $178,840 |
| EliquisApixaban | 84 | $63,802 |
| XareltoRivaroxaban | 26 | $23,159 |
| Imatinib Mesylate | 18 | $22,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $754,338 | $997,19372 claims |
| Bristol Myers SquibbRevlimid | $41,854 | $907,81068 claims |
| Astellas Pharma US IncXtandi | $120 | $765,81660 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $94 | $525,02828 claims |
| Johnson & JohnsonErleada, Xarelto | $12 | $290,91845 claims |
| AbbVieVenclexta | $149,634 | $270,61724 claims |
| Incyte CorporationJakafi | $12 | $251,40119 claims |
| PfizerEliquis | $95 | $63,80284 claims |
| Lilly USA, LLCOlanzapine | $12 | $19322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Chattanooga
- Bertrand AnzChattanooga$9.6M
- Edward ArrowsmithChattanooga$5.7M
- Davey DanielChattanooga$5M
- Brooke DanielChattanooga$4M
- Robert GrahamChattanooga$799K
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.